PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
D. Planchard(Université Paris-Saclay), P.A. Jänne(Dana-Farber Cancer Institute), K. Kobayashi(Saitama International Medical Center), J.C.-H. Yang(National Taiwan University Hospital), Y. Liu(Jilin Province Tumor Hospital), Natalia Valdiviezo(Instituto Nacional de Enfermedades Neoplásicas), T.M. Kim(New Generation University College), Lingxiang Jiang(Shanghai Chest Hospital), H. Kagamu(Saitama Medical University), N. Yanagitani(Japanese Foundation For Cancer Research), J. Wang(Fudan University Shanghai Cancer Center), Bivas Biswas(Tata Medical Center), Artem Poltoratskiy(Institute of Oncology NN Petrov), Yeni Nerón(Centro de Pesquisas Oncológicas), Celeste Rojas(Bradford Teaching Hospitals NHS Foundation Trust), Leona Koubková(University Hospital in Motol), Carles Escriu(Clatterbridge Cancer Centre NHS Foundation Trust), Doreen A. Ezeife(University of Calgary), K. Barrett(AstraZeneca (Singapore)), Muna Albayaty(AstraZeneca (Poland)), Haiyi Jiang(AstraZeneca (Netherlands)), Chee Khoon Lee(St George Hospital)
Cited by 10
Abstract
Related Papers
No related papers found
Powered by citation graph analysis